The new label was first reported by Timothy Anderson, an analyst at Prudential Equity Group.
Both departures were first reported by Timothy Anderson, an analyst at Prudential Equity Group.
"I don't think these results help, " says Timothy Anderson, an analyst at Prudential Equity Group.
David Woodburn, an analyst for Prudential Equity Group, has a "sell" rating on Seprecor.
Timothy Anderson of Prudential Equity Group says that this generic "cliff" is the largest in the history of pharma.
"More than anything else, they've put fun back in the cereal aisle, " says Prudential Equity Group analyst John McMillin.
Timothy Anderson, an analyst at Prudential Equity Group, wrote in a note to investors that the statement worried him.
Timothy Anderson of Prudential Equity Group says that this generic "cliff" is the largest in the history of pharmaceutical companies.
Timothy Anderson, an analyst at Prudential Equity Group, first reported the likely labeling change in a note to investors Friday night.
Brands may well be hampered in the near term by vagaries around the globe, according to Prudential Equity Group analyst Larry Miller.
Lawrence Biegelsen, an analyst at Prudential Equity Group, has written that the stent makers are likely to be hurt by the study.
Timothy Anderson, an analyst at Prudential Equity Group, was the first to report the news in a note to investors this morning.
In a note to investors on March 10, analyst Timothy Anderson at Prudential Equity Group predicted that Asteroid would come out positive.
This group of demanding investment firms includes Goldman Sachs (with just 24% of its recommendations positive), Morgan Stanley (32%), Prudential Equity Group (32%), A.G.
Even with home values down--80% of the market is distressed sales, says Dan DeNuccio, a real estate broker with Prudential Americana Group in Las Vegas.
Timothy Anderson, an analyst at Prudential Equity Group, was the first to report the news of Sheares' departure in a note to investors this morning.
Under the tutelage of new chief Joseph Gromek it looks as if the company is getting a second wind, says Lizabeth Dunn, analyst at Prudential Equity Group.
Merck could be looking at flat earnings growth in 2007 and 2008, wrote Timothy Anderson, an analyst at Prudential Equity Group, in a note to investors today.
That decision could prove wise in the long term, says Prudential Equity Group analyst Mark Lipacis, who wrote in a research note that the deal makes strategic sense.
In a note to investors last week, Prudential Equity Group analyst Timothy Anderson wrote that Merck Chief Executive RichardClarkRichard Clark says Vioxx doesn't keep him up at night.
Timothy Anderson, an analyst at Prudential Equity Group, predicts the result will at the least hurt Avandia sales as patients switch to competing medicines from Merck and Takeda.
In a note to investors last week, Prudential Equity Group analyst Timothy Anderson wrote that Merck Chief Executive Richard Clark says Vioxx doesn't keep him up at night.
Prudential Financial, the life insurance company (and owner of Prudential Equity Group, one of our demanding brokerages), is poised to improve earnings through its rapidly growing international business, says A.G.
Timothy Anderson, an analyst at Prudential Equity Group who is neutral on Merck shares, wrote in a note to investors that the decision was on balance a negative for Merck.
In a report last week, Tim Anderson, a sell-side analyst at Prudential Equities group, predicted that the Premarin trial would be ending early (see " Wyeth's Premarin Trial Seen Ending Early").
Timothy Anderson, an analyst at Prudential Equity Group, wrote in a note yesterday that liver toxicities seen with Prexige could be a commercial "deal killer" but that the results may help Merck.
As written by Prudential Equity Group analyst Timothy Anderson last week, a patent battle GlaxoSmithKline (nyse: GSK - news - people ) lost might bode well for the Zyprexa decision.
In September, as it became clear that Dolan was on his way out, Timothy Anderson, an analyst at Prudential Equity Group, went from telling investors to sell Bristol shares to suggesting they buy them.
Timothy Anderson, who covers Roche for Prudential Equity Group, suggested in a note to investors that 10% of patients in the U.S. who could benefit from Herceptin in early breast cancer could already be on the drug.
In a note Thursday morning, Timothy Anderson of Prudential Equity Group said he did not expect a clear answer from the torcetrapib study and that there would need to be "soul searching" for companies developing rival drugs.
应用推荐